ClinicalTrials.gg
RecruitingNCT05772481TEPIRECUpdated Jun 17, 2026

Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

An observational study in Rectal Cancer, sponsored by Centre Paul Strauss. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Centre Paul Strauss · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 160 studies in Rectal Neoplasms with a site in France — 28 open to participants now, 40 under way, 6 of them phase 3. Rectal Neoplasms · France.

Planned enrollment
20th of 27
50 · median 100
Started
2023
with 5 others
Observational
27 of 160
10 open now
Primary completion
2026-09
later than 13 of 39 live
Registered
135th of 160
by date

Among the 160 studies in Rectal Neoplasms with a site in France, this one is the 20th largest by planned enrollment of the 27 observational ones that give a count, is one of 6 that started in 2023, is one of 27 observational ones, reaches primary completion later than 13 of the 39 other live ones, and was the 135th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

28 of the 160 studies in Rectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Rectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

With 50 patients included, this trial would be the largest pilot study evaluating the value of MRI PET in locally advanced rectal cancer. On the other hand, it would be the only pilot study performing several MRI PET during neoadjuvant treatment. Presumably, the response assessed at the 2nd MRI PET (before cycle 4 or induction chemotherapy) would be predictive of the overall response at the end of neoadjuvant treatment. Then, it would be possible to predict precociously the tumor response.

Read the detailed description

The management of localized rectal cancer is done in two phases. The first phase, medical, combines a possible first chemotherapy, followed by a concomitant chemoradiotherapy. The second phase, 6 to 8 weeks later, consists of surgery of the rectum.

Magnetic resonance imaging (MRI) of the pelvis allows staging of the tumor and its possible lymph node extensions. MRI can also be used to assess tumor response after the first phase of treatment and before surgery. But MRI of the pelvis is partially imperfect.

PET-MRI is an examination that combines MRI with an injection of [18 F]fluorodeoxyglucose (18F-FDG). It is known to be more sensitive in assessing tumor stage and lymph node extensions compared to MRI and more sensitive in assessing tumor response before surgery.

The aim of this study is to determine predictive parameters for response to the first phase of treatment by accurately identifying the characteristics of tumors that have responded or not to treatment with chemotherapy and chemoradiotherapy.

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patient with histologically proven rectal cancer with an indication for induction chemotherapy followed by neoadjuvant chemoradiotherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • World Health Organization (WHO)/ (ECOG) 0 to 2
  • proven rectal cancer
  • clinical tumor classification (cT) : cT3 - cT4 or all T / N+ / M0
  • Tumor resectable or considered resectable after chemoradiotherapy
  • Decision chemotherapy followed by chemoradiotherapy decided at the organ Multidisciplinary Meeting
  • Absence of distant
  • Adequate for women of
  • Free, signed and
  • For women of childbearing potential : negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Subject with Uncontrolled diabetes
  • to surgery
  • Contraindication to MRI
  • Contraindication to PET scan
  • Contraindication to chemotherapy
  • History of pelvic radiotherapy
  • History of major co-morbidity that may prevent treatment and no active infection ( or chronic or C)
  • Colloid (mucinous) adenocarcinoma
  • Presence of distant
  • Contraindication to 5-FluoroUracil (FU), oxaliplatin or irinotecan
  • History of known Gilbert's disease
  • Patient with known UGT1A1 genotype
  • Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
  • Medical history of chronic diarrhea or inflammatory disease of the colon or rectum
  • Medical history of angina or myocardial infarction.
  • Active progressive infection or any other serious medical condition that could compromise the administration of the treatment
  • Other concurrent cancer, or medical history of cancer other than treated in situ cervical carcinoma or basal cell carcinoma or squamous cell carcinoma
  • Patient enrolled in another clinical trial testing an agent
  • Pregnant or breastfeeding woman
  • Persons deprived of their freedom or under guardianship or incapable of giving consent
  • Any psychological, familial, sociological or geographic condition that may interfere with the study protocol or follow-up schedule
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult population with rectal cancer

    Other: PET-MRI

Interventions

  • OtherPET-MRI

    Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment. Induction chemotherapy may be performed at another center than the investigating center. After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed. A 3rd PET-MRI will be performed prior to radiation therapy (PET-MRI 3). A final MRI PET (MRI PET 4) will take place before surgery. A total of 4 PET MRI scans will be performed.

06

What researchers measure

Primary outcomes

  1. Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of metabolic criteria.

    The purpose of this study is to determine predictive parameters for response to the first phase of treatment by accurately identifying the characteristics of tumors that have responded or not to chemotherapy and chemoradiotherapy. Metabolic criteria will be measured with the SUVmax values that will be determined on the 4 PET-MRI scans.

    Time frame: At the surgery

  2. Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of MRI criteria.

    MRI criteria will be measured with the Apparent Diffusion Coefficient (ADC) values that will be determined on the 4 PET-MRI scans.

    Time frame: At the surgery

  3. Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of anatomopathological criteria.

    Anatomopathological criteria will be measured with the histopathological response to treatment which will be defined according to the tumor regression grade (TRG)

    Time frame: At the surgery

Secondary outcomes

  1. Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of tumor volumes

    Record of tumor volumes on MRI PET 1

    Time frame: At the PET MRI pretherapy (= PET MRI 1)

  2. Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of SUVmax values

    Record of SUVmax on MRI PET 1

    Time frame: At the PET MRI pretherapy (= PET MRI 1)

  3. Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of ADC values

    Record of ADC on MRI PET 1

    Time frame: At the PET MRI pretherapy (= PET MRI 1)

  4. Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta tumor volume

    Record of delta tumor volume, compared to baseline (PET MRI 1)

    Time frame: At the 2nd PET (PET2), up to 28 months

  5. Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta SUVmax values

    Record of delta SUVmax, compared to baseline (PET MRI 1)

    Time frame: At the 2nd PET (PET2), up to 28 months

  6. Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta ADC values

    Record of delta ADC, compared to baseline (PET MRI 1)

    Time frame: At the 2nd PET (PET2), up to 28 months

  7. Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta tumor volume

    Record of delta tumor volume, compared to baseline (PET MRI 1)

    Time frame: At the 3rd PET (PET3), up to 28 months

  8. Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta SUVmax values

    Record of delta SUVmax, compared to baseline (PET MRI 1)

    Time frame: At the 3rd PET (PET3), up to 28 months

  9. Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta ADC values

    Record of delta ADC, compared to baseline (PET MRI 1)

    Time frame: At the 3rd PET (PET3), up to 28 months

  10. Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta tumor volume

    Record of delta tumor volume, compared to PET3

    Time frame: At the 4th PET (PET4), up to 28 months

  11. Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta SUVmax values

    Record of delta SUVmax, compared to PET3

    Time frame: At the 4th PET (PET4), up to 28 months

  12. Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta ADC values

    Record of delta ADC, compared to PET3

    Time frame: At the 4th PET (PET4), up to 28 months

  13. Propose standardized criteria to differentiate responders from non-responders

    Record of clinical and iconographic data predictive of good response to treatment

    Time frame: Data record throughout the study, up to 28 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Sep 2026, 39 months after the start.

Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 39 months is below that.

Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Mar 16, 2023
StartActual
May 19, 2023
Primary completionEst.
Sep 18, 2026
CompletionEst.
Jul 25, 2030
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05772481
Lead sponsor
Centre Paul Strauss
Responsible party
Sponsor
First posted
Mar 16, 2023
Start date
May 19, 2023
Primary completion
Sep 18, 2026 (estimated)
Completion
Jul 25, 2030 (estimated)
Last update
Jun 17, 2026

Study contacts

Manon VOEGELIN
Contact
promotion-rc@icans.eu
+33 6 68 33 95 23
Claire VIT
Contact
promotion-rc@icans.eu
+ 33 6 68 33 95 23

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion